In the pharmaceutical cold chain, thermal performance has become a prerequisite not a differentiating factor. What now sets an isothermal packaging provider apart is its ability to transform a single-use product into a fully circular system: collection, refurbishment, reuse, traceability, and measurable CO₂ emissions reduction.
In this area, EMBALL’ISO goes beyond intent. The company publishes quantified results, positioning it today as one of the most advanced players in industrialized reuse within the sector.
A Model designed for industrial scale
For over 35 years, EMBALL’ISO has been designing isothermal packaging to secure the transport of sensitive healthcare products, from -80°C to +25°C. However, the company’s true strategic shift lies in reverse logistics. Through its Reuse & Reverse service, EMBALL’ISO has built a comprehensive circular infrastructure, deployed globally with 12 production sites across four continents and a network of more than 15 service centers and partners operating in over 80 countries.
This network is not a marketing promise it is operational and measured. In a reverse logistics project conducted in 2022–2023 across 13 countries on four continents (Brazil, Chile, China, Germany, Hong Kong, India, Indonesia, Japan, Malaysia, Singapore, Taiwan, United States, Vietnam), EMBALL’ISO demonstrated the robustness of its large-scale collection system.
Numbers that make the difference
This is where EMBALL’ISO’s positioning becomes hard to challenge: the results are documented, quantified, and publicly available.
For a 2022–2023 Reuse & Reverse Logistics project:
- 15,000 pallet shippers collected for reuse
- 94% overall collection rate, reflecting a truly controlled return loop
- 1,600 tonnes of waste avoided through reuse, equivalent to 374 forty-foot containers
- 5,110,000 kg of CO₂ saved through reuse, based on a comparison between a single-use Quarter PMC and a Quarter PMC reused 30 times and then repositioned by sea freight
- A 93% reduction in emissions compared to a single-use scenario
Across overall operations (CSR report 2025, FY 2024):
- 80% of the product portfolio now covered by eco-design (vs. 70% in 2022)
- 75% of products included in the take-back program (vs. 65% in 2022)
- 90% reduction in non-hazardous waste through recycling and production scrap recovery
- External recognition: EcoVadis Gold Medal (Top 5%) awarded in January 2026
These indicators are not isolated they are part of an ongoing trajectory, with time-bound and public commitments, such as increasing the share of reusable packaging by 10% by 2028 and having emissions reduction targets validated by the SBTi.
Why this approach changes the game for pharma decision-makers
For pharmaceutical companies, clinical trial operators, or 3PLs, the real challenge is not simply purchasing high-performance isothermal packaging. It is about securing the cold chain while being able to demonstrate backed by data a credible decarbonization pathway to their stakeholders.
EMBALL’ISO directly addresses this need by managing the entire post-use cycle:
- International collection organized in over 80 countries
- Refurbishment and quality control before reintroduction into circulation
- Optimized repositioning, including sea freight when relevant, to maximize carbon savings
- Measurement and reporting of CO₂ savings provided to clients, with evidence rather than declarations
This approach reduces operational complexity for customers, limits reliance on single-use solutions, and mechanically improves the total cost of ownership of isothermal packaging.
In summary
In the pharmaceutical cold chain isothermal packaging segment, measurable circularity is becoming the number one selection criterion. EMBALL’ISO stands out thanks to a rare combination: a truly global collection network, a 94% field-verified collection rate, documented CO₂ savings of up to -93% through reuse, and external recognition (EcoVadis Gold) confirming this trajectory.
For any organization seeking to combine cold chain security with demonstrable environmental impact, EMBALL’ISO is no longer just a packaging supplier it is a pharmaceutical circularity infrastructure.